Daniel Lietha was awarded one of the research grants of the Spanish Association Against Cancer in Madrid

The Spanish Association Against Cancer in Madrid, committed to promoting cancer research and exceeding the 70% survival rate in 2030, and as a sign of support for research talent, presented the fifty-four new AECC 2024 grants awarded in the Community of Madrid last Thursday, February 13. The total investment in this item exceeds five million euros (5,127,134 €).

Daniel Lietha, a researcher at the Margarita Salas Center for Biological Research (CSIC) has been awarded for his project “Could an innovative artificial intelligence technology revolutionize cancer treatment?” with an investment of €128,420.96.

In addition, Alejandro Fuentes and Antonio Asensio received grants from the Summer Laboratory Internship Program AECC 2024, for stays at the CIB Margarita Salas.

Jaime Salaverri, president of the AECC in Madrid; Nieves Mijimolle, vice-president of the AECC Scientific Foundation, and Ms. Inmaculada Ibáñez de Cáceres, director general of Research and Teaching of the Regional Ministry of Health of the Community of Madrid, participated in the opening of the awards ceremony, held at the AECC headquarters in Madrid.

The research grants awarded range from pre-doctoral and talent attraction (AECC Talent) to consolidated projects and international collaboration networks (TRANSCAN-3). They are focused on topics such as small-cell lung cancer, childhood leukemia, or the possibilities presented by using artificial intelligence to revolutionize treatments.

The award ceremony for the fifty-four project grants included two round tables: one on support for talent and the other on research into low-survival cancers.

The AECC 2024 Grants cover all phases of the research career focusing on increasing funding with a special focus on low-survival cancers, attracting research talent to promote the employment stability of researchers, promoting innovation and clinical research so that the results reach the patient, and fostering clinical research.